Roche (RHHBY) shares fell the most in nearly two months Wednesday after the Swiss drugmaker's Tecentriq oncology treatment fell short in a key clinical trial for use as a bladder cancer treatment.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks